Rivaroxaban is an oral anticoagulant that selectively inhibits factor xa in the coagulation cascade. The inhibition prevents the conversion of prothrombin to thrombin thereby reducing thrombin generation. By limiting thrombin it decreases the formation of fibrin clots that can block blood vessels. The medication is used to prevent stroke in patients with atrial fibrillation and to treat or prevent deep vein thrombosis and pulmonary embolism. Rivaroxaban offers predictable oral bioavailability and typically does not require routine laboratory monitoring. Its pharmacologic effect is reversible and the drug is cleared mainly through renal excretion. It produces its antithrombotic action by binding directly to factor xa and decreasing the amount of active enzyme available for clot formation.

Rivaroxaban is an oral medication that helps prevent harmful blood clots. It works by blocking a protein called factor xa that is essential for clot formation. Blocking factor xa reduces the production of thrombin, the enzyme that creates fibrin strands. The decrease in thrombin limits the growth and formation of new clots in arteries and veins. Doctors prescribe it to lower the risk of stroke in patients with an irregular heartbeat. It is also used to treat and prevent deep vein thrombosis and pulmonary embolism.

Rivaroxaban may cause bleeding that ranges from minor bruising to more serious internal hemorrhage. Common symptoms include nosebleeds or gum bleeding that are usually short lived. Some patients experience dizziness or lightheadedness especially when standing up quickly. Fatigue or weakness can occur as a reaction to changes in blood pressure. Headache is reported by a small number of users during therapy. In rare cases, allergic reactions such as rash or swelling may develop. Gastrointestinal discomfort including nausea or abdominal pain has been observed. Swelling of the ankles or feet may indicate fluid retention in some individuals.

Rivaroxaban can increase the risk of bleeding, including nosebleeds and gum bleeding. Some people experience nausea or mild stomach discomfort after taking the medication. Headaches are reported by a modest number of users during treatment. Fatigue or general weakness may occur, especially when blood pressure changes. Dizziness or light-headedness can appear, particularly when standing up quickly. Rare cases of anemia have been noted due to reduced red blood cell counts. Elevations in liver enzymes have been observed in occasional laboratory tests. In some instances, allergic skin reactions such as rash or itching may develop.